Clinical Trial: Treatment of neutropenic patients with fever who are suspected to have a gram positive infection (a specific kind of bacteria)

This study has been completed.

Sponsored by: Pfizer
Information provided by: Pfizer

Purpose

This study will treat patients who have fever and neutropenia (after cancer chemotherapy) that is possibly due to a specific bacteria (gram positive bacteria)

Condition Treatment or Intervention Phase
Neutropenia
Fever
Gram-Positive Bacterial Infections
Neoplasms
 Drug: Antibiotic
 Drug: Vancomycin
Phase III

MedlinePlus related topics:  Bacterial Infections;   Blood and Blood Disorders;   Cancer;   Cancer Alternative Therapy;   Fever

Study Type: Interventional
Study Design: Treatment

Eligibility

Ages Eligible for Study:  13 Years and above,  Genders Eligible for Study:  Both

Criteria

Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary.

Inclusion Criteria:

  • Patients must have neutropenia (ANC less than 500) with fever (oral temp 38.3 C).
  • Patients must have a cancer with recent chemotherapy and risks factors for gram positive infections.

Exclusion Criteria:

  • Patients with fever due to known causes.
  • Patients with HIV.
  • Patients with recent bone marrow transplant.
  • Patients with an infected indwelling catheter that cannot be removed.
  • Patients who have received more than one day of another antibiotic before entering the trial.
  • Patients with endocarditis, osteomyelitis, meningitis, CNS infections.

Location Information


California
      Research Center, San Diego,  California,  92134,  United States

      Research Center, Los Angeles,  California,  90033,  United States

      Research Center, Orange,  California,  92868,  United States

Florida
      Research Center, Miami,  Florida,  33136,  United States

Illinois
      Research Center, Springfield,  Illinois,  62701,  United States

      Research Center, Maywood,  Illinois,  60153,  United States

Kentucky
      Research Center, Lexington,  Kentucky,  40536,  United States

Massachusetts
      Research Center, Worcester,  Massachusetts,  01655,  United States

Michigan
      Research Center, Kalamazoo,  Michigan,  49001,  United States

New Jersey
      Research Center, Perth Amboy,  New Jersey,  08861,  United States

New York
      Research Center, Bronx,  New York,  10467-2490,  United States

Ohio
      Research Center, Youngstown,  Ohio,  44501,  United States

Tennessee
      Research Center, Jackson,  Tennessee,  38301,  United States

Texas
      Research Center, Houston,  Texas,  77030-4211,  United States

      Research Center, Houston,  Texas,  77030,  United States

Virginia
      Research Center, Richmond,  Virginia,  23249,  United States

      Research Center, Falls Church,  Virginia,  22042,  United States

      Research Center, Richmond,  Virginia,  23294,  United States

Washington
      Research Center, Tacoma,  Washington,  98405,  United States

Wisconsin
      Research Center, Milwaukee,  Wisconsin,  53226,  United States

Puerto Rico
      Research Center, Hato Rey,  00985,  Puerto Rico

More Information

Study ID Numbers:  M/1260/0079
Record last reviewed:  March 2004
Last Updated:  October 13, 2004
Record first received:  May 3, 2002
ClinicalTrials.gov Identifier:  NCT00035425
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Resources